YM BioSciences, Inc. (AMEX: YMI) is on The StockGuru Leader Board today.  The stock closed up 4.37% on Wednesday.

Volume was 1,838,256 shares traded.

Join in on the Discussion about YMIhttp://members.stockguru.com/stocks/ymi/

About the Company:

YM BioSciences Inc., a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. Its products include CYT387, a small molecule dual inhibitor of the JAK1/JAK2 kinases that is in Phase I/II clinical trial for the treatment of patients with myelofibrosis, a chronic debilitating disease; and CYT 997, an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and has completed a Phase II trial in glioblastoma multiforme. The company is also developing Nimotuzumab, a humanized monoclonal antibody, which is in various Phase II and III trials worldwide targeting EGFR with an enhanced side-effect profile over currently marketed EGFR-targeting antibodies. In addition, it has various preclinical research programs underway with candidates from its library of compounds identified through internal research. The company was formerly known as York Medical Inc. and changed its name to YM Biosciences Inc. in February 2001. YM BioSciences Inc. was founded in 1994 and is headquartered in Mississauga, Canada.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact: [email protected].

StockGuru.com
StockGuruCanada.com
Shareholdervision.com
BoldStocks.com
IR Affiliates – IRIR.co
StoneBridge Web & SEO – StonebridgeIQ.com

All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: [email protected] or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070